Geron Corporation (NASDAQ: GERN)

Geron Corporation (NASDAQ: GERN) is a biopharmaceutical company focused on developing biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including heart failure, spinal cord injury and diabetes. The company’s mission is to develop an array of anti-cancer therapies based on telomerase inhibitors, telomerase therapeutic vaccines, and telomerase-based oncolytic viruses, and diagnostics based on telomerase detection. For further information, visit the Company’s web site at www.geron.com.